Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
Edgewise Therapeutics Chief Medical Officer Joanne M. Donovan sold 28,662 shares of common stock on April 1, 2026, for about $926,095 under a pre-arranged Rule 10b5-1 plan and concurrently exercised options to acquire the same number of shares at $7.08 each. The stock is trading near its 52-week high and appears overvalued versus InvestingPro's Fai…
Terrance Lane Wilson, senior vice president and general counsel of Williams Companies, sold 2,000 shares of the company's common stock on April 1, 2026, for $71.75 per share, realizing $143,500. The transaction was carried out under a 10b5-1 trading plan and leaves Wilson with 289,159 shares directly and 100 shares indirectly through a trust. Separ…
EOG Resources Executive Vice President and COO Jeffrey R. Leitzell executed a series of stock transactions on March 31, 2026, including an outright sale and multiple dispositions tied to the exercise of stock appreciation rights (SARs), while also acquiring shares through SAR exercises. The moves came as EOG reported mixed fourth-quarter 2025 resul…
Lynx1 Capital Management L.P., a roughly 10% holder of Korro Bio, Inc. (NASDAQ: KRRO), purchased 520 shares of common stock on March 31, 2026, at $10.60 per share for a total of $5,512. The company’s shares have since traded up to $13.85, a roughly 30% increase from the purchase price. Korro Bio has also announced an $85 million private equity fina…
Carnival director Sir Jonathon Band sold a total of 12,000 Carnival Corp (CCL) shares in two transactions that together amounted to $314,265. The trades occurred on March 31 and April 1, 2026. The company recently reported first-quarter 2026 results that modestly exceeded expectations on adjusted EBITDA and adjusted EPS, while analysts issued a ran…
Carnival Plc director Sir Jonathon Band sold 12,000 Trust Shares in two transactions on March 31 and April 1, 2026, realizing $314,265. The trades occurred at prices between $24.982 and $26.19, modestly above the stocks current quote of $25.65. After the disposals, Sir Jonathon Band holds 52,601.3359 Trust Shares directly. InvestingPro analysis cit…
On April 1, 2026, Lawrence T. Oliver, Senior Vice President and Secretary of RGC Resources Inc (RGCO), acquired 9.238 shares at $21.65, a transaction valued at roughly $200. The move comes while the utility's shares trade near a 52-week high and following a first-quarter report that missed EPS estimates but topped revenue expectations. The company …
RGC Resources Vice President of Human Resources Miles Christen Brooke purchased 4.619 shares of common stock on April 1, 2026, for a total of $100 under the company’s Dividend Reinvestment and Stock Purchase Plan. The company reported first-quarter fiscal 2026 earnings per share of $0.47, below analysts' $0.54 forecast, while revenue came in at $30…
William A. Richardson disposed of 20,000 shares of Gold.com, Inc. (NASDAQ:GOLD) on March 31, 2026, for $40.00 per share, realizing $800,000. The transaction occurred while the shares traded near $40.91, following a roughly 70% return over the prior 12 months. Gold.com finalized acquisition of the remaining 55.1% of Sunshine Minting, Inc., and annou…
Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares on April 1, 2026 under a Rule 10b5-1 plan, generating $199,616 in proceeds. The transaction comes amid recent equity offerings and analyst price-target increases tied to a collaboration with Astellas Pharma; Vir's shares have returned 59% over the past six months.
A Tivic Health director purchased 19,000 shares on April 1, 2026, totaling $18,008, according to a Form 4 filing. The transaction occurs as the company transitions from consumer devices to a biopharmaceutical focus and secures funding for preclinical Entolimod studies aimed at protecting against lethal radiation exposure.
Princeton Bancorp director Stephen Shueh bought a total of 10,500 common shares in two transactions, bringing his direct stake to 42,038 shares. The purchases, totaling $297,395, occurred on May 15, 2023 and May 3, 2024. The company also announced a quarterly cash dividend of $0.35 per share payable February 27, 2026 to holders of record on Februar…
Scynexis INC Chief Executive Officer David Angulo Gonzalez purchased 108,695 shares at $0.92 per unit in a private placement on April 1, 2026, and received warrants for an equal number of shares. The move accompanies a planned roughly $40 million financing, recent clinical-stage milestones for SCY-247 and analyst price targets in the $3 to $4 range…
Comstock Inc. director Leo M. Drozdoff purchased 28,000 shares on March 30, 2026, spending roughly $84,000. The acquisition comes as the recycler and metals-focused company reports a negative gross profit margin and recent balance-sheet adjustments, including an amendment to a promissory note with Georges Trust and a reported doubling of its asset …
Luminus Management LLC, a roughly 10% holder and director at Battalion Oil Corp (BATL), sold 1,890,481 common shares across March 30-31, 2026, realizing about $8.6 million. The activity included conversion of preferred stock into common shares and the relinquishment of cash-settled total return swap rights. The transactions occurred as the company’…
Slide Insurance Holdings Inc. (SLDE) President and COO Shannon Lucas sold 38,686 shares under a prearranged 10b5-1 plan between March 30 and April 1, 2026, generating roughly $700,004. The filings also show Lucas exercised stock options for 45,838 shares at no cost on March 31, 2026, and relinquished 9,019 shares to satisfy tax obligations. After t…
Slide Insurance Holdings Chief Executive Bruce Lucas sold 381,855 shares of common stock between March 30 and April 1, 2026, generating about $7.07 million through trades executed under a 10b5-1 plan. On March 31 he also sold 9,019 shares to meet tax obligations and exercised 22,919 RSUs at $0 per share. The company recently reported robust fourth-…
John P. Schmid, a director at AnaptysBio (ANAB), sold 20,645 shares of common stock on March 30, 2026, for a total of $1.16 million across multiple transactions. The company is proceeding with the spinout of First Tracks Biotherapeutics, which has secured $80 million in a private placement ahead of a planned distribution on April 20, 2026, and Anap…
Matthew Paul Larson, Chief Risk Officer at Slide Insurance Holdings (NASDAQ: SLDE), sold 11,250 shares on March 30, 2026, for $202,500 and simultaneously exercised and sold 11,250 options at $0.79 each. The trades were executed under a pre-arranged 10b5-1 plan adopted December 4, 2025. Slide reported robust fourth-quarter 2025 earnings and announce…
Alset International Ltd sold 100,390 shares of HWH International Inc on March 30, 2026 at a weighted average price of $0.983, generating $98,683 in proceeds. The sale left Alset International Limited with an indirect holding of 1,891,279 HWH shares. Separately, HWH has agreed to buy 99.55% of Hapi Metaverse Inc for $19.9 million via a five-year pro…
Christopher Longhito, Senior Vice President and Chief Supply Chain Officer at Global Industrial Co (NASDAQ: GIC), sold a total of $385,013 in common stock across multiple transactions from March 23 to March 27, 2026. On March 27 he also exercised options that cost $131,775. Following the reported trades and exercises, Longhito is listed as owning z…
Trupanion Inc.’s Chief Operating Officer John R. Gallagher sold 430 shares on March 30, 2026, at $25.47 per share, yielding $10,952. The transaction, executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, leaves Gallagher with 31,957 shares. The stock is trading near its 52-week low of $24.32 and is down 41% over the past six months.…
Karen Krasney, Executive Vice President and General Counsel of Capricor Therapeutics (NASDAQ: CAPR), sold 25,000 shares on March 31, 2026 for $752,935 and simultaneously exercised options to acquire 25,000 shares. The disposal was carried out under a pre-established 10b5-1 trading plan. Capricor recently reported a Q4 fiscal 2025 EPS miss and conti…
Capricor Therapeutics CFO Anthony Bergmann sold 25,000 shares on March 31, 2026, under a 10b5-1 plan for roughly $753,152 and exercised options to acquire 25,000 shares at $3.18 each. The moves come as the company faces an earnings shortfall, analyst price targets that exceed current trading levels, and an upcoming PDUFA date for deramiocel.
A director of RH sold 11,000 shares on March 31, 2026, generating roughly $1.5 million in proceeds across multiple trades. The director also exercised options to acquire 11,000 shares at $39.42. The moves come as RH stock has fallen sharply over the past year and several brokerages have trimmed price targets following disappointing quarterly result…
